within Pharmacolibrary.Drugs.M_MusculoSkeletalSystem.M03A_MuscleRelaxantsPeripherallyActingAgents.M03AC11_Cisatracurium;

model Cisatracurium
  extends Pharmacolibrary.Drugs.ATC.M.M03AC11;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>M03AC11</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Cisatracurium is a non-depolarizing neuromuscular blocking agent used for skeletal muscle relaxation during surgical procedures and mechanical ventilation in intensive care units. It is a benzylisoquinolinium compound and is approved for clinical use today, particularly favored due to organ-independent metabolism (Hofmann elimination), making it suitable for patients with hepatic or renal impairment.</p><h4>Pharmacokinetics</h4><p>Typical pharmacokinetics in healthy adult patients after single intravenous bolus dose; parameters largely independent of age and sex due to predominant Hoffman elimination.</p><h4>References</h4><ol><li><p>Kisor, DF, &amp; Schmith, VD (1999). Clinical pharmacokinetics of cisatracurium besilate. <i>Clinical pharmacokinetics</i> 36(1) 27–40. DOI:<a href=&quot;https://doi.org/10.2165/00003088-199936010-00003&quot;>10.2165/00003088-199936010-00003</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/9989341/&quot;>https://pubmed.ncbi.nlm.nih.gov/9989341</a></p></li><li><p>Huang, X, et al., &amp; Wang, S (2020). Abnormal cisatracurium pharmacodynamics and pharmacokinetics among patients with severe aortic regurgitation during anesthetic induction. <i>BMC anesthesiology</i> 20(1) 21–None. DOI:<a href=&quot;https://doi.org/10.1186/s12871-020-0935-z&quot;>10.1186/s12871-020-0935-z</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/31969113/&quot;>https://pubmed.ncbi.nlm.nih.gov/31969113</a></p></li><li><p>Wu, Z, et al., &amp; Wu, B (2016). Altered Cisatracurium Pharmacokinetics and Pharmacodynamics in Patients with Congenital Heart Defects. <i>Drug metabolism and disposition: the biological fate of chemicals</i> 44(1) 75–82. DOI:<a href=&quot;https://doi.org/10.1124/dmd.115.067405&quot;>10.1124/dmd.115.067405</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/26470914/&quot;>https://pubmed.ncbi.nlm.nih.gov/26470914</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Cisatracurium;
